psychiatric disease; behavioral disorder

From Aaushi
Jump to navigation Jump to search

Clinical manifestations

  • psychiatric disease manifests itself through behavioral disturbances

Laboratory

* laboratory associatios with risk of psychiatric disease

Complications

Management

* adjusted hazzard ratios statistically significant, but modest & of unclear clinical significance (swedish study)

More general terms

More specific terms

Additional terms

References

  1. 1.0 1.1 Lawrence D et al. The gap in life expectancy from preventable physical illness in psychiatric patients in western australia: retrospective analysis of population based registers. BMJ 2013 May 21; 346:f2539. PMID: https://www.ncbi.nlm.nih.gov/pubmed/23694688
  2. Huhn M et al. Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: a systematic overview of meta-analyses. JAMA Psychiatry 2014 apr 30 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24789675 <Internet> http://archpsyc.jamanetwork.com/article.aspx?articleid=1865002
    Correll CU, Carbon M. Efficacy of pharmacologic and psychotherapeutic interventions in psychiatry: to talk or to prescribe: is that the question? JAMA Psychiatry 2014 apr 30 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24789579 <Internet> http://archpsyc.jamanetwork.com/article.aspx?articleid=1865001
  3. Montross C Hard time or hospital treatment? Mental illness and the criminal justice system. N Engl J Med 2016; 375:1407-1409. october 13, 2016 http://www.nejm.org/doi/full/10.1056/nejmp1606083
  4. 4.0 4.1 Bowling A, slavet j, miller dp et al Cybercycling effects on classroom behavior in children with behavioral health disorders: an rct. pediatrics. january 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28069663 <Internet> http://pediatrics.aappublications.org/content/early/2017/01/05/peds.2016-1985
  5. 5.0 5.1 5.2 Jayes JF, lundin a, wicks s et al Association of hydroxylmethyl glutaryl coenzyme a reductase inhibitors, l-type calcium channel antagonists, and biguanides with rates of psychiatric hospitalization and self-harm in individuals with serious mental illness. JAMA Psychiatry published online january 9, 2019. PMID: https://www.ncbi.nlm.nih.gov/pubmed/30624557 https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2719703
  6. 6.0 6.1 Plana-Ripoll O, Pedersen CB, Holtz Y et al. Exploring comorbidity within mental disorders among a danish national population. JAMA Psychiatry 2019 jan 16; PMID: https://www.ncbi.nlm.nih.gov/pubmed/30649197
    Hyman SE. New evidence for shared risk architecture of mental disorders. JAMA Psychiatry2019 jan 16 pmid: https://www.ncbi.nlm.nih.gov/pubmed/30649144
  7. Zeng Y, Chourpiliadis C, Hammar N et al Inflammatory biomarkers and risk of psychiatric disorders. JAMA Psychiatry. 2024 aug 21:e242185. pmid: https://www.ncbi.nlm.nih.gov/pubmed/39167384 https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2822344
  8. Ardila A. Psychiatric disorders associated with acquired brain pathology. Appl Neuropsychol Adult. 2019;26(6):591-597 PMID: https://www.ncbi.nlm.nih.gov/pubmed/30183352 Review. https://www.tandfonline.com/doi/full/10.1080/23279095.2018.1463224